Summary:
This is a multi-center, randomized, double-blind, placebo-controlled study in up to approximately 540 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the study will be approximately 74 weeks, which includes an up to 8-week screening period, a 53-week treatment period, and a 13-week post-treatment evaluation period or transition to open-label extension (OLE) study with up to 1-year treatment.
Qualified Participants Must:
• Be 18 years or older
• have a fasting triglycerides level greater than 500
Qualified Participants May Receive:
Medical care, Medicaiton, and Compensation for time and travel.